Jazayeri-Tehrani et al. examined the effects of nanocurcumin on overweight/obese non-alcoholic fatty liver disease (NAFLD) patients by assessing glucose, lipids, inflammation, insulin resistance, and liver function indices, especially through nesfatin. The gene discussed is NUCB2; the disease is metabolic dysfunction-associated steatotic liver disease.